Bellerophon Therapeutics (NASDAQ:BLPH) Earns Sell Rating from Analysts at initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

BLPH has been the topic of a number of other research reports. Brookline Capital Management decreased their price objective on shares of Bellerophon Therapeutics from $26.00 to $19.00 in a research report on Monday, April 4th. Brookline Capital Acquisition reduced their price target on shares of Bellerophon Therapeutics from $26.00 to $19.00 in a research report on Monday, April 4th. Finally, Zacks Investment Research cut shares of Bellerophon Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 19th.

Shares of NASDAQ BLPH opened at $1.99 on Monday. Bellerophon Therapeutics has a fifty-two week low of $1.77 and a fifty-two week high of $5.95. The stock has a market cap of $18.99 million, a price-to-earnings ratio of -1.06 and a beta of -0.54. The firm’s 50-day simple moving average is $2.18 and its 200 day simple moving average is $2.83.

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) last announced its quarterly earnings results on Thursday, March 31st. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.15. As a group, equities analysts predict that Bellerophon Therapeutics will post -2.16 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. Millennium Management LLC acquired a new position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,243 shares of the biotechnology company’s stock, valued at approximately $59,000. Millennium Management LLC owned approximately 0.13% of Bellerophon Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.20% of the company’s stock.

About Bellerophon Therapeutics (Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

See Also

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.